NRX Pharmaceuticals IncNASDAQ:NRXPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.6900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6900/ 2
- Ask / Lots1.8000/ 4
- Open / Previous Close--- / 1.6900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXP |
|---|---|---|
| 09:32 ET | 7788 | 1.77 |
| 09:38 ET | 1362 | 1.73 |
| 09:39 ET | 500 | 1.71 |
| 09:41 ET | 400 | 1.7862 |
| 09:52 ET | 112 | 1.7742 |
| 09:57 ET | 828 | 1.77 |
| 09:59 ET | 812 | 1.7406 |
| 10:01 ET | 150 | 1.77 |
| 10:06 ET | 150 | 1.765 |
| 10:08 ET | 100 | 1.74 |
| 10:21 ET | 2589 | 1.72 |
| 10:26 ET | 400 | 1.74 |
| 10:28 ET | 1600 | 1.73 |
| 10:30 ET | 700 | 1.715 |
| 10:32 ET | 4738 | 1.68 |
| 10:33 ET | 3287 | 1.69 |
| 10:35 ET | 100 | 1.69 |
| 10:37 ET | 1000 | 1.69 |
| 10:44 ET | 300 | 1.69 |
| 10:50 ET | 784 | 1.7 |
| 10:51 ET | 1100 | 1.71 |
| 10:55 ET | 1400 | 1.7 |
| 10:57 ET | 800 | 1.69 |
| 11:00 ET | 2800 | 1.67 |
| 11:02 ET | 300 | 1.67 |
| 11:04 ET | 2600 | 1.68 |
| 11:06 ET | 100 | 1.675 |
| 11:08 ET | 1384 | 1.68 |
| 11:13 ET | 224 | 1.695 |
| 11:20 ET | 597 | 1.6802 |
| 11:27 ET | 100 | 1.69 |
| 11:29 ET | 2800 | 1.685 |
| 11:31 ET | 250 | 1.685 |
| 11:40 ET | 100 | 1.685 |
| 11:44 ET | 398 | 1.6899 |
| 11:45 ET | 510 | 1.685 |
| 11:47 ET | 220 | 1.685 |
| 12:21 ET | 100 | 1.685 |
| 12:25 ET | 11509 | 1.68 |
| 12:43 ET | 100 | 1.68 |
| 12:54 ET | 565 | 1.68 |
| 12:56 ET | 100 | 1.67 |
| 01:10 ET | 300 | 1.675 |
| 01:12 ET | 1054 | 1.65 |
| 01:17 ET | 144 | 1.66 |
| 01:35 ET | 100 | 1.665 |
| 01:53 ET | 100 | 1.66 |
| 02:06 ET | 190 | 1.663 |
| 02:11 ET | 1980 | 1.67 |
| 02:13 ET | 100 | 1.6999 |
| 02:44 ET | 100 | 1.7 |
| 03:03 ET | 100 | 1.685 |
| 03:14 ET | 2140 | 1.67 |
| 03:23 ET | 300 | 1.6701 |
| 03:34 ET | 600 | 1.6759 |
| 03:38 ET | 100 | 1.675 |
| 03:43 ET | 200 | 1.67 |
| 03:48 ET | 200 | 1.67 |
| 03:56 ET | 2619 | 1.68 |
| 03:57 ET | 100 | 1.685 |
| 03:59 ET | 2516 | 1.69 |
Yesterday
Sep 12, 2024
DJ NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital, from 2:08PM ET on Thursday Sep 12, 2024 by Dow Jones
2:08PM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 11, 2024
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com, from 7:55AM ET on Wednesday Sep 11, 2024 by Dow Jones
7:55AM ET on Wednesday Sep 11, 2024 by Dow Jones
Sep 3, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NRX Pharmaceuticals Inc | 18.2M | -1.0x | --- |
Biomx Inc | 18.3M | -2.2x | --- |
Biora Therapeutics Inc | 18.3M | -0.1x | --- |
Brainstorm Cell Therapeutics Inc | 18.4M | -15.4x | --- |
Cocrystal Pharma Inc | 17.9M | -1.0x | --- |
Minerva Neurosciences Inc | 18.7M | -0.6x | --- |
Company Information
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Contact Information
- Headquarters
- 1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801
- Phone
- 484-254-6134
- Fax
- 302-575-1642
Executives
- Chairman of the Board, Chief Scientific Officer
- Jonathan Javitt
- Chief Executive Officer, Director
- Stephen Willard
- Interim Chief Financial Officer
- Richard Narido
- CMC and Technical Operations Advisor
- Riccardo Panicucci
- Independent Director
- Patrick Flynn
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $-1.62 |
Book Value | $-0.14 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
